The patent has been granted The patent has been granted, Grant of patent is intended, Examination is in progress, Request for examination was made EP Register Verified

STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS

Publication No. EP4541379

•

App No. EP25162390

•

Filed by Advanced Accelerator Applications S.A.

•

Filed on 2018-09-25

•

Issued/Published on 2025-11-19

Official EPO Register

Publication No. EP4541379 A2

Application No. EP25162390 Filed: 2018-09-25

Grant Date 2025-11-19 Mention of grant

Active Oppositions 2 Active EPO Oppositions

Patent Abstract / Summary

[0001] The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

IPC Classifications

A61K51/08, A61P35/00, A61K103/30, A61K9/00, A61K9/08, A61K47/12, A61K47/22, A61K51/12 A61K51/08

Priority Claims

WO 2018IB55575 Date: 2018-07-25

US 201816045484 Date: 2018-07-25

Designated Contracting States (38 EPC States)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Parties & Representation

Applicants

Advanced Accelerator Applications S.A.

8 rue Henri Sainte-Claire Deville, CS10150

Inventors (7)

CHICCO, Daniela

86077 Pozzilli Isernia

BARBATO, Donato

86077 Pozzilli Isernia

DE PALO, Francesco

86077 Pozzilli Isernia

FUGAZZA, Lorenza

86077 Pozzilli Isernia

MARIANI, Maurizio

86077 Pozzilli Isernia

TESORIERE, Giovanni

86077 Pozzilli Isernia

BRAMBATI, Clementina

86077 Pozzilli Isernia

Representatives / Agents

Carpmaels & Ransford LLP

One Southampton Row, London WC1B 5HA

Maiwald GmbH

Elisenhof, Elisenstraße 3

Watermeyer, Nicholas

Withers & Rogers LLP, 2 London Bridge

Key Procedural Dates

Request-For-Examination 2025-03-07

Mention Of Grant Published 2025-11-19

First-Examination-Report-Despatched 2025-07-04

Patent Oppositions

Official opposition proceedings filed against European Patent EP4541379 under EPC Article 99.

2 ACTIVE OPPONENTS

Opponent Company

Lumara Bio Oncologics GmbH

Lichtenbergstraße 1, DE

Representative

Maiwald GmbH

Filing Date

2026-08-17

Opposition in Progress

Opponent Company

Withers & Rogers LLP

2 London Bridge, GB

Representative

Watermeyer, Nicholas

Filing Date

2026-08-19

Opposition in Progress

Legal Status & Event History

Official European Patent Office legal and procedural status changes recorded for this file.

54 Events Recorded

Date	Code	Event Description	Auth
2025-04-23	17P	REQUEST FOR EXAMINATION FILED	EP
2025-04-23	AC	DIVISIONAL APPLICATION: REFERENCE TO EARLIER APPLICATION	EP
2025-04-23	AK	DESIGNATED CONTRACTING STATES	EP
2025-03-21	PUAI	PUBLIC REFERENCE MADE UNDER ARTICLE 153(3) EPC TO A PUBLISHED INTERNATIONAL APPLICATION THAT HAS ENTERED THE EUROPEAN PHASE	EP
2025-03-21	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2025-06-20	PUAL	SEARCH REPORT DESPATCHED	EP
2025-07-04	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2025-07-23	RIC1	INFORMATION PROVIDED ON IPC CODE ASSIGNED BEFORE GRANT	EP
2025-07-23	AK	DESIGNATED CONTRACTING STATES	EP
2025-07-25	REG	REFERENCE TO A NATIONAL CODE	EP
2025-07-30	P01	OPT-OUT OF THE COMPETENCE OF THE UNIFIED PATENT COURT (UPC) REGISTERED	EP
2025-08-06	17Q	FIRST EXAMINATION REPORT DESPATCHED	EP
2025-08-13	RAP3	PARTY DATA CHANGED (APPLICANT DATA CHANGED OR RIGHTS OF AN APPLICATION TRANSFERRED)	EP
2025-09-24	TPAC	OBSERVATIONS FILED BY THIRD PARTIES	EP
2025-09-26	GRAP	DESPATCH OF COMMUNICATION OF INTENTION TO GRANT A PATENT	EP
2025-09-26	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2025-10-01	GRAS	GRANT FEE PAID	EP
2025-10-15	RIC1	INFORMATION PROVIDED ON IPC CODE ASSIGNED BEFORE GRANT	EP
2025-10-17	GRAA	(EXPECTED) GRANT	EP
2025-10-17	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2025-10-29	INTG	INTENTION TO GRANT ANNOUNCED	EP
2025-11-19	AC	DIVISIONAL APPLICATION: REFERENCE TO EARLIER APPLICATION	EP
2025-11-19	AK	DESIGNATED CONTRACTING STATES	EP
2025-11-19	REG	REFERENCE TO A NATIONAL CODE	EP
2025-12-11	REG	REFERENCE TO A NATIONAL CODE	EP
2025-12-17	REG	REFERENCE TO A NATIONAL CODE	EP
2026-01-29	REG	REFERENCE TO A NATIONAL CODE	EP
2026-02-11	REG	REFERENCE TO A NATIONAL CODE	EP
2026-02-02	REG	REFERENCE TO A NATIONAL CODE	EP
2026-02-17	REG	REFERENCE TO A NATIONAL CODE	EP
2018-09-25	REG	REFERENCE TO A NATIONAL CODE	EP
2026-03-16	REG	REFERENCE TO A NATIONAL CODE	EP
2026-03-25	REG	REFERENCE TO A NATIONAL CODE	EP
2026-04-10	REG	REFERENCE TO A NATIONAL CODE	EP
2026-04-16	REG	REFERENCE TO A NATIONAL CODE	EP
2026-04-08	REG	REFERENCE TO A NATIONAL CODE	EP
2026-04-28	REG	REFERENCE TO A NATIONAL CODE	EP
2026-07-03	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-08-15	REG	REFERENCE TO A NATIONAL CODE	EP
2026-08-21	PLBI	OPPOSITION FILED	EP
2026-08-26	REG	REFERENCE TO A NATIONAL CODE	EP
2026-08-30	PLAX	NOTICE OF OPPOSITION AND REQUEST TO FILE OBSERVATION + TIME LIMIT SENT	EP
2026-08-17	REG	REFERENCE TO A NATIONAL CODE	EP
2026-09-16	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-09-22	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-09-23	26	OPPOSITION FILED	EP
2026-10-01	REG	REFERENCE TO A NATIONAL CODE	EP
2026-10-09	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-10-10	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-10-09	REG	REFERENCE TO A NATIONAL CODE	EP
2026-10-13	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-10-14	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-10-15	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-10-16	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP

Patent & Non-Patent Citations

Cited documents and prior art referenced in search and examination reports.

42 Citations

Cited Patent Documents

WO2008009444

Espacenet

US6780996

Espacenet

WO02066470

Espacenet

US5621002

Espacenet

WO03064383

Espacenet

WO03077914

Espacenet

WO0035436

Espacenet

WO0206213

Espacenet

US2779780

Espacenet

WO2007014011

Espacenet

WO03076424

Espacenet

US4261989

Espacenet

Non-Patent Scientific Literature (NPL)

- DAS ET AL., J RADIOANAL NUCL CHEM, vol. 299, 2014, pages 1389 - 1398

- DAS ET AL., CURRENT RADIOPHARMACEUTICALS, vol. 7, 2014, pages 12 - 19

- LUNA-GUTIERREZ ET AL., J RADIOANAL NUCL CHEM, vol. 314, 2017, pages 2181 - 2188

- MATHUR ET AL., CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, vol. 32, no. 7, 2017, pages 266 - 273

- no. 1204531-25-80

- DE BLOIS ERIK, CHAN HO SZE, DE ZANGER RORY, KONIJNENBERG MARK, BREEMAN WOUTER A.P.: "Application of single-vial ready-for-use formulation of 111In- or 177Lu-labelled somatostatin analogs", APPLIED RADIATION AND ISOTOPES, vol. 85, 1 February 2014 (2014-02-01), GB , pages 28 - 33, XP093117067, ISSN: 0969-8043, DOI: 10.1016/j.apradiso.2013.10.023

- ANUPAM MATHUR ET AL: "Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use 177 Lu-DOTA-TATE: The Intricate Radiochemistry Aspects", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 32, no. 7, 1 September 2017 (2017-09-01), US, pages 266 - 273, XP055558673, ISSN: 1084-9785, DOI: 10.1089/cbr.2017.2208

- STEPHAN MAUS ET AL: "Aspects on radiolabeling of 177Lu-DOTA-TATE: After C18 purification re-addition of ascorbic acid is required to maintain radiochemical purity", INTERNATIONAL JOURNAL OF DIAGNOSTIC IMAGING, SCIEDU PRESS, CA, vol. 1, no. 1, 1 March 2014 (2014-03-01), pages 5 - 11, XP002738789, ISSN: 2331-5857, [retrieved on 20140221], DOI: 10.5430/IJDI.V1N1P5

- LUNA-GUTI�RREZ MYRNA ET AL: "Freeze-dried multi-dose kits for the fast preparation of177Lu-Tyr3-octreotide and177Lu-PSMA(inhibitor) under GMP conditions", JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, AKADEMIAI KIADO RT, HU, vol. 314, no. 3, 2 November 2017 (2017-11-02), pages 2181 - 2188, XP036380439, ISSN: 0236-5731, [retrieved on 20171102], DOI: 10.1007/S10967-017-5595-1

- DE BARBOZA M ET AL: "PRODUCTION and QUALITY CONTROL of 177 Lu-DOTATATE [ 177 Lu-DOTA-Tyr3]-OCTREOTATE: CLINICAL APPLICATION", 31 December 2009 (2009-12-31), XP093192831, Retrieved from the Internet <URL:https://inis.iaea.org/collection/NCLCollectionStore/_Public/43/004/43004240.pdf>

- DE BARBOZA M ET AL: "PRODUCTION AND QUALITY CONTROL OF 177 LU-DOTATATE [ 177 LU-DOTA-TRY3]-OCTREOTATE: CLINICAL APPLICATION", 31 December 2009 (2009-12-31), XP093192833, Retrieved from the Internet <URL:https://inis.iaea.org/collection/NCLCollectionStore/_Public/43/005/43005461.pdf>

- EMA: "Assessment report: Lutathera", 17 January 2018 (2018-01-17), XP093192834, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/documents/assessment-report/lutathera-epar-public-assessment-report_en.pdf>

- ADVANCED ACCELERATOR APPLICATIONS USA, INC: "HIGHLIGHTS OF PRESCRIBING INFORMATION - LUTATHERA", HTTPS://WWW.ADACAP.COM/WP-CONTENT/UPLOADS/2018/01/LUTATHERA_LUTETIUM_LU_-177_DOTATATE_PI_2018_01.PDF, ADVANCED ACCELERATOR APPLICATIONS USA, INC, 27 January 2018 (2018-01-27), pages 1 - 14, XP093427664, Retrieved from the Internet <URL:https://web.archive.org/web/20180127133211/https://www.adacap.com/wp-content/uploads/2018/01/Lutathera_lutetium_Lu_-177_dotatate_PI_2018_01.pdf>

- D1a - Screenshot of web page of wayback machine proving that D1 was published on the webpage of Advanced Accelerator Applications (www.adacap.com) on 27 January 2018

- STROSBERG JONATHAN, EL-HADDAD GHASSAN, WOLIN EDWARD, HENDIFAR ANDREW, YAO JAMES, CHASEN BETH, MITTRA ERIK, KUNZ PAMELA L., KULKE M: "Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 376, no. 2, 12 January 2017 (2017-01-12), US, pages 125 - 135, XP093427666, ISSN: 0028-4793, DOI: 10.1056/nejmoa1607427

- D2a - Supplementary Appendix to D2 titled “Protocol”

- D2b - Email exchange with the Editorial Team of The New England Journal of Medicine confirming that D2a was in fact published on 11 January 2017

- Screenshot of web page of wayback machine proving that D3 was published on the webpage of the European Medicines Agency on January 2018

- BREEMAN WOUTER A.P., SZE CHAN HO, M.S. DE ZANGER RORY, K. KONIJNENBERG MARK, DE BLOIS ERIK: "Overview of Development and Formulation of 177Lu-DOTA-TATE for PRRT", CURRENT RADIOPHARMACEUTICALS, vol. 9, no. 1, 1 April 2016 (2016-04-01), pages 8 - 18, XP093427681, ISSN: 1874-4710, DOI: 10.2174/1874471008666150313111131

- ROOHI SAMINA, RIZVI SHAKERA KHATOON, NAQVI SYED ALI RAZA: "177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Indigenously Developed Freeze Dried Cold Kit and Biological Response in In-Vitro and In-Vivo Models", DOSE-RESPONSE, vol. 19, no. 1, 1 January 2021 (2021-01-01), US , pages 1 - 9, XP093427685, ISSN: 1559-3258, DOI: 10.1177/1559325821990147

- ASTI MATTIA; ATTI GIULIA; IORI MICHELE; FARIOLI DANIELA; FILICE ANGELINA; VERSARI ANNIBALE: "Semiautomated labelling and fractionation of yttrium-90 and lutetium-177 somatostatin analogues using disposable syringes and vials.", NUCLEAR MEDICINE COMMUNICATIONS, vol. 33, no. 11, 1 November 2012 (2012-11-01), pages 1144 - 1152, XP009176319, ISSN: 0143-3636, DOI: 10.1097/MNM.0b013e328358131f

- ANONYMOUS: "19th European Symposium on Radiopharmacy and Radiopharmaceuticals (ESRR’18)", EJNMMI RADIOPHARMACY AND CHEMISTRY, SPRINGER SCIENCE AND BUSINESS MEDIA LLC, vol. 3, 1 May 2018 (2018-05-01) - 2018-04-08, pages 1 - 38, XP093427691, DOI: 10.1186/s41181-018-0041-4 * PP08 - Production of Lutetium-177 DOTATATE/PSMA-617 on a MultiSyn radio-synthesizer module for use in Molecular Radiotherapy, page 19 - page 19 *

- STEPHAN MAUS, ERIK DE BLOIS, STEPHAN J. AMENT, MATHIAS SCHRECKENBERGER, WOUTER A. P. BREEMAN: "Aspects on radiolabeling of 177Lu-DOTA-TATE: After C18 purification re-addition of ascorbic acid is required to maintain radiochemical purity", INTERNATIONAL JOURNAL OF DIAGNOSTIC IMAGING, vol. 1, no. 1, 1 March 2014 (2014-03-01), CA , pages 5 - 11, XP002738789, ISSN: 2331-5857, DOI: 10.5430/ijdi.v1n1p5

- JOLANTA KUNIKOWSKA; LESZEK KRóLICKI; ALICJA HUBALEWSKA-DYDEJCZYK; RENATA MIKOłAJCZAK; ANNA SOWA-STASZCZAK; DARIUSZ PAWLA: "Clinical results of radionuclide therapy of neuroendocrine tumours withY-DOTATATE and tandemY/Lu-DOTATATE: which is a better therapy option?", EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 38, no. 10, 7 May 2011 (2011-05-07), DE, pages 1788 - 1797, XP019949149, ISSN: 1619-7089, DOI: 10.1007/s00259-011-1833-x

- KWEKKEBOOM D J, ET AL.: "¬177LU-DOTA0,TYR3¾OCTREOTATE: COMPARISON WITH ¬111IN-DTPAO¾OCTREOTIDE IN PATIENTS", EUROPEAN JOURNAL OF NUCLEAR MEDICINE, SPRINGER, BERLIN, HEIDELBERG, DE, vol. 28, no. 09, 1 September 2001 (2001-09-01), Berlin, Heidelberg, DE , pages 1319 - 1325, XP001088577, ISSN: 0340-6997, DOI: 10.1007/s002590100574

- ANUPAM MATHUR, VRINDA PRASHANT, NAVIN SAKHARE, SUDIPTA CHAKRABORTY, K.V. VIMALNATH, REPAKA KRISHNA MOHAN, CHANDA ARJUN, BARKHA KAR: "Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use 177 Lu-DOTA-TATE: The Intricate Radiochemistry Aspects", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 32, no. 7, 1 September 2017 (2017-09-01), US , pages 266 - 273, XP055558673, ISSN: 1084-9785, DOI: 10.1089/cbr.2017.2208

- MUKHERJEE ARCHANA, LOHAR SHARAD, DASH ASHUTOSH, SARMA HALADHAR DEV, SAMUEL GRACE, KORDE ARUNA: "Single vial kit formulation of DOTATATE for preparation of 177 Lu-labeled therapeutic radiopharmaceutical at hospital radiopharmacy", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 58, no. 4, 1 April 2015 (2015-04-01), US, pages 166 - 172, XP055928600, ISSN: 0362-4803, DOI: 10.1002/jlcr.3267

- DAS TAPAS, BANERJEE SHARMILA, SHINTO AJIT, KAMALESHWARAN K.K., SARMA H.D.: "Preparation of Therapeutic Dose of 177Lu-DOTA-TATE Using a Novel Single Vial Freeze-dried Kit: A Comparison with ‘In-situ’ Preparation at Hospital Radiopharmacy", CURRENT RADIOPHARMACEUTICALS, vol. 7, no. 1, 1 April 2014 (2014-04-01), pages 12 - 19, XP093427703, ISSN: 1874-4710, DOI: 10.2174/1874471007666140605100812

- CHEN, J. LINDER, K.E. CAGNOLINI, A. METCALFE, E. RAJU, N. TWEEDLE, M.F. SWENSON, R.E.: "Synthesis, stabilization and formulation of [^1^7^7Lu]Lu-AMBA, a systemic radiotherapeutic agent for Gastrin Releasing Peptide receptor positive tumors", APPLIED RADIATION AND ISOTOPES, vol. 66, no. 4, 19 November 2007 (2007-11-19), GB , pages 497 - 505, XP022498787, ISSN: 0969-8043

- LIDGETT ADAM: "Patent Claims On Novartis Unit Drug Invalid, Del. Judge Says", HTTPS://WWW.LAW360.COM, PORTFOLIO MEDIA, INC., US, 18 June 2026 (2026-06-18), US, pages 1 - 2, XP093427707, Retrieved from the Internet <URL:https://www.law360.com/articles/2487682/patent-claims-on-novartis-unit-drug-invalid-del-judge-says>

Worldwide Patent Family

Related applications and patents in the same INPADOC worldwide family.

196 Family Members

Country	Publication Number	Kind	Publication Date	Action
EP	EP4541379A2	A2	2025-04-23	Espacenet
EP	EP4541379A3	A3	2025-07-23	Espacenet
EP	EP4541379B1	B1	2025-11-19	Espacenet
AR	AR119655A1	A1	2022-01-05	Espacenet
AU	AU2018433575A1	A1	2021-02-11	Espacenet
AU	AU2018433575B2	B2	2022-07-07	Espacenet
AU	AU2022203683A1	A1	2022-06-16	Espacenet
AU	AU2022203683B2	B2	2023-12-21	Espacenet
AU	AU2024201217A1	A1	2024-03-14	Espacenet
AU	AU2024201217B2	B2	2025-02-27	Espacenet
AU	AU2025202231A1	A1	2025-04-17	Espacenet
AU	AU2025202231B2	B2	2026-05-14	Espacenet
AU	AU2025204901A1	A1	2025-07-17	Espacenet
AU	AU2025204901B2	B2	2025-09-18	Espacenet
AU	AU2025220852A1	A1	2025-09-11	Espacenet
AU	AU2025220852B2	B2	2025-10-23	Espacenet
AU	AU2026204487A1	A1	2026-07-02	Espacenet
AU	AU2026210852A1	A1	2026-08-20	Espacenet
BR	BR112021001148A2	A2	2021-04-20	Espacenet
CA	CA3153630A1	A1	2020-01-30	Espacenet
CN	CN112584875A	A	2021-03-30	Espacenet
CN	CN112867512A	A	2021-05-28	Espacenet
CN	CN112955188A	A	2021-06-11	Espacenet
CN	CN117122707A	A	2023-11-28	Espacenet
CN	CN120860270A	A	2025-10-31	Espacenet
CN	CN120860271A	A	2025-10-31	Espacenet
CN	CN120860272A	A	2025-10-31	Espacenet
CN	CN121081692A	A	2025-12-09	Espacenet
CO	CO2021000506A2	A2	2021-04-19	Espacenet
DE	DE202018006567U1	U1	2021-02-22	Espacenet
DE	DE202018007006U1	U1	2025-10-08	Espacenet
DE	DE202018007007U1	U1	2025-10-08	Espacenet
DK	DK3826686T3	T3	2025-08-25	Espacenet
DK	DK4541379T3	T3	2026-02-02	Espacenet
DK	DK4541380T3	T3	2026-02-23	Espacenet
DK	DK4541381T3	T3	2026-04-07	Espacenet
DK	DK4545100T3	T3	2026-02-23	Espacenet
DK	DK4545101T3	T3	2026-03-02	Espacenet
DK	DK4640241T3	T3	2026-07-27	Espacenet
EP	EP3826686A1	A1	2021-06-02	Espacenet
EP	EP3826686B1	B1	2025-05-21	Espacenet
EP	EP3826687A1	A1	2021-06-02	Espacenet
EP	EP3856262A1	A1	2021-08-04	Espacenet
EP	EP4541380A2	A2	2025-04-23	Espacenet
EP	EP4541380A3	A3	2025-07-23	Espacenet
EP	EP4541380B1	B1	2025-12-10	Espacenet
EP	EP4541381A2	A2	2025-04-23	Espacenet
EP	EP4541381A3	A3	2025-07-23	Espacenet
EP	EP4541381B1	B1	2026-02-04	Espacenet
EP	EP4545100A2	A2	2025-04-30	Espacenet
EP	EP4545100A3	A3	2025-07-23	Espacenet
EP	EP4545100B1	B1	2025-12-10	Espacenet
EP	EP4545101A2	A2	2025-04-30	Espacenet
EP	EP4545101A3	A3	2025-07-23	Espacenet
EP	EP4545101B1	B1	2025-12-10	Espacenet
EP	EP4640241A2	A2	2025-10-29	Espacenet
EP	EP4640241A3	A3	2025-12-10	Espacenet
EP	EP4640241B1	B1	2026-06-03	Espacenet
EP	EP4810070A2	A2	2026-09-23	Espacenet
EP	EP4810070A3	A3	2026-10-07	Espacenet
ES	ES3038413T3	T3	2025-10-13	Espacenet
ES	ES3063402T3	T3	2026-04-16	Espacenet
ES	ES3064434T3	T3	2026-04-24	Espacenet
ES	ES3064589T3	T3	2026-04-27	Espacenet
ES	ES3065583T3	T3	2026-05-06	Espacenet
ES	ES3067415T3	T3	2026-05-21	Espacenet
ES	ES3077045T3	T3	2026-08-25	Espacenet
FI	FI3826686T3	T3	2025-08-20	Espacenet
FI	FI4541379T3	T3	2026-02-17	Espacenet
FI	FI4541380T3	T3	2026-03-02	Espacenet
FI	FI4541381T3	T3	2026-04-01	Espacenet
FI	FI4545100T3	T3	2026-03-02	Espacenet
FI	FI4545101T3	T3	2026-02-24	Espacenet
FI	FI4640241T3	T3	2026-07-21	Espacenet
HR	HRP20250912T1	T1	2025-09-26	Espacenet
HR	HRP20260100T1	T1	2026-04-10	Espacenet
HR	HRP20260179T1	T1	2026-04-10	Espacenet
HR	HRP20260222T1	T1	2026-03-27	Espacenet
HR	HRP20260237T1	T1	2026-04-10	Espacenet
HR	HRP20260338T1	T1	2026-04-10	Espacenet
HR	HRP20260911T1	T1	2026-10-09	Espacenet
HU	HUE072720T2	T2	2025-12-28	Espacenet
IL	IL280314A	A	2021-03-25	Espacenet
IL	IL280314B1	B1	2026-07-01	Espacenet
IL	IL313560A	A	2024-08-01	Espacenet
IL	IL313560B1	B1	2025-07-01	Espacenet
IL	IL313560B2	B2	2025-11-01	Espacenet
IL	IL319541A	A	2025-05-01	Espacenet
IL	IL319541B1	B1	2025-09-01	Espacenet
IL	IL319541B2	B2	2026-01-01	Espacenet
IL	IL319542A	A	2025-05-01	Espacenet
IL	IL319542B1	B1	2026-04-01	Espacenet
IL	IL319542B2	B2	2026-08-01	Espacenet
IL	IL326944A	A	2026-05-01	Espacenet
JP	JP2021531306A	A	2021-11-18	Espacenet
JP	JP2022500355A	A	2022-01-04	Espacenet
JP	JP7358451B2	B2	2023-10-10	Espacenet
JP	JP2022501313A	A	2022-01-06	Espacenet
JP	JP7402218B2	B2	2023-12-20	Espacenet
JP	JP2022502505A	A	2022-01-11	Espacenet
JP	JP7358484B2	B2	2023-10-10	Espacenet
JP	JP2023107801A	A	2023-08-03	Espacenet
JP	JP2023117417A	A	2023-08-23	Espacenet
JP	JP7796696B2	B2	2026-01-09	Espacenet
JP	JP2023126209A	A	2023-09-07	Espacenet
JP	JP2024038132A	A	2024-03-19	Espacenet
JP	JP2025060775A	A	2025-04-10	Espacenet
JP	JP2025094124A	A	2025-06-24	Espacenet
JP	JP2025111424A	A	2025-07-30	Espacenet
JP	JP2025183243A	A	2025-12-16	Espacenet
JP	JP2026136123A	A	2026-08-25	Espacenet
KR	KR20210035855A	A	2021-04-01	Espacenet
KR	KR102643582B1	B1	2024-03-05	Espacenet
KR	KR20240033296A	A	2024-03-12	Espacenet
KR	KR102865113B1	B1	2025-09-26	Espacenet
KR	KR20250017751A	A	2025-02-04	Espacenet
KR	KR102932818B1	B1	2026-03-03	Espacenet
KR	KR20260030955A	A	2026-03-06	Espacenet
LT	LT3826686T	T	2025-08-25	Espacenet
LT	LT4541379T	T	2026-02-10	Espacenet
LT	LT4541380T	T	2026-03-10	Espacenet
LT	LT4541381T	T	2026-03-25	Espacenet
LT	LT4545100T	T	2026-02-25	Espacenet
LT	LT4545101T	T	2026-03-10	Espacenet
LT	LT4640241T	T	2026-07-27	Espacenet
MX	MX2021000805A	A	2021-05-12	Espacenet
MX	MX430346B	B	2026-01-21	Espacenet
MX	MX2025012060A	A	2025-11-03	Espacenet
PL	PL3826686T3	T3	2025-09-22	Espacenet
PL	PL4541379T3	T3	2026-03-23	Espacenet
PL	PL4541380T3	T3	2026-03-30	Espacenet
PL	PL4541381T3	T3	2026-05-11	Espacenet
PL	PL4545100T3	T3	2026-03-30	Espacenet
PL	PL4545101T3	T3	2026-03-30	Espacenet
PL	PL4640241T3	T3	2026-08-31	Espacenet
PT	PT3826686T	T	2025-08-04	Espacenet
PT	PT4541379T	T	2026-01-29	Espacenet
PT	PT4541380T	T	2026-02-24	Espacenet
PT	PT4541381T	T	2026-03-17	Espacenet
PT	PT4545100T	T	2026-02-16	Espacenet
PT	PT4545101T	T	2026-02-24	Espacenet
PT	PT4640241T	T	2026-07-17	Espacenet
RS	RS67034B1	B1	2025-08-29	Espacenet
RS	RS67667B1	B1	2026-02-27	Espacenet
RS	RS67729B1	B1	2026-03-31	Espacenet
RS	RS67754B1	B1	2026-03-31	Espacenet
RS	RS67755B1	B1	2026-03-31	Espacenet
RS	RS67864B1	B1	2026-04-30	Espacenet
RS	RS68308B1	B1	2026-07-31	Espacenet
SG	SG11202100645XA	A	2021-02-25	Espacenet
SI	SI3826686T1	T1	2025-09-30	Espacenet
SI	SI4541379T1	T1	2026-03-31	Espacenet
SI	SI4541380T1	T1	2026-04-30	Espacenet
SI	SI4541381T1	T1	2026-05-29	Espacenet
SI	SI4545100T1	T1	2026-03-31	Espacenet
SI	SI4545101T1	T1	2026-04-30	Espacenet
SI	SI4640241T1	T1	2026-09-30	Espacenet
TW	TW202019489A	A	2020-06-01	Espacenet
TW	TWI888355B	B	2025-07-01	Espacenet
TW	TW202517302A	A	2025-05-01	Espacenet
TW	TW202517303A	A	2025-05-01	Espacenet
US	US2020030464A1	A1	2020-01-30	Espacenet
US	US10596276B2	B2	2020-03-24	Espacenet
US	US2020030467A1	A1	2020-01-30	Espacenet
US	US10596278B2	B2	2020-03-24	Espacenet
US	US2020353106A1	A1	2020-11-12	Espacenet
US	US11904027B2	B2	2024-02-20	Espacenet
US	US20240285812A1	A1	2024-08-29	Espacenet
US	US12144873B2	B2	2024-11-19	Espacenet
US	US20240285811A1	A1	2024-08-29	Espacenet
US	US12151003B2	B2	2024-11-26	Espacenet
US	US20240285813A1	A1	2024-08-29	Espacenet
US	US12161732B2	B2	2024-12-10	Espacenet
US	US20240285814A1	A1	2024-08-29	Espacenet
US	US12168063B2	B2	2024-12-17	Espacenet
US	US20250082790A1	A1	2025-03-13	Espacenet
US	US12415003B2	B2	2025-09-16	Espacenet
US	US20250082791A1	A1	2025-03-13	Espacenet
US	US12491272B2	B2	2025-12-09	Espacenet
US	US2020030465A1	A1	2020-01-30	Espacenet
US	US2020030466A1	A1	2020-01-30	Espacenet
US	US2021346527A1	A1	2021-11-11	Espacenet
US	US2021379212A1	A1	2021-12-09	Espacenet
US	US2021379213A1	A1	2021-12-09	Espacenet
US	US2022072166A1	A1	2022-03-10	Espacenet
US	US20240075171A1	A1	2024-03-07	Espacenet
US	US20250025583A1	A1	2025-01-23	Espacenet
US	US20250049969A1	A1	2025-02-13	Espacenet
US	US20250213734A1	A1	2025-07-03	Espacenet
US	US20250295820A1	A1	2025-09-25	Espacenet
US	US20260174912A1	A1	2026-06-25	Espacenet
US	US20260256961A1	A1	2026-09-03	Espacenet
WO	WO2020021310A1	A1	2020-01-30	Espacenet
WO	WO2020021322A1	A1	2020-01-30	Espacenet
WO	WO2020021465A1	A1	2020-01-30	Espacenet
WO	WO2020064693A1	A1	2020-04-02	Espacenet

Official File Inspection EPC Art. 128 Public Dossier

Complete European Patent Register Dossier (148 Total Documents)

The full inspection file for Application EP25162390 contains 148 total documents, including all notices of opposition, proprietor counter-statements, examination communications, third-party observations, and procedural forms. Below are all major recorded procedural filings and publication specifications.

Open 148-Doc Register Dossier

Dossier Filing

Date: 2025-10-01 Procedure: Examination EPIDOSNIGR5

Inspect on Register

STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS

Patent Abstract / Summary

IPC Classifications

Priority Claims

Designated Contracting States (38 EPC States)

Parties & Representation

Applicants

Inventors (7)

Representatives / Agents

Key Procedural Dates

Patent Oppositions

Lumara Bio Oncologics GmbH

Withers & Rogers LLP

Legal Status & Event History

Patent & Non-Patent Citations

Cited Patent Documents

Non-Patent Scientific Literature (NPL)

Worldwide Patent Family

Complete European Patent Register Dossier (148 Total Documents)

Recorded Filings & Patent Specifications

European Patent Specification - Granted Patent (B1)

Official European Patent Register Full Dossier

European Search Report (A3)

European Patent Application without Search Report (A2)

Invitation to proprietor to file observations on the notice of opposition

New entry: Communication of a notice of opposition and request to file observations + time limit

Opposition filed

Lapse of the patent in a contracting state

(Expected) grant

New entry: Receipt of the translation of the claim(s)

New entry: Payment of fee for grant

New entry: Payment of fee for publishing/printing

New entry: Communication of intention to grant a patent

Intention to grant the patent

New entry: Observations by third parties

Observations by a third party

Change - classification

New entry: Renewal fee paid

Renewal fee payment

New entry: Reply to examination report

Change - applicant

New entry: Despatch of examination report + time limit

First examination report

Communication from the examining division

Date on which the examining division has become responsible

Change - classification

Publication of search report

The date on which the examining division becomes responsible, has been established

Publication in section I.1 EP Bulletin

Request for examination filed

New entry: Renewal fee paid

Change - representative

Renewal fee payment

Language of the procedure

International searching authority